Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024
Medical cannabis: update on the final year of testing and the arrival of cannabis-based medicines
https://ansm.sante.fr/actualites/cannabis-medical-point-detape-sur-la-derniere-annee-de-lexperimentation-et-larrivee-de-medicaments-a-base-de-cannabis
Multi-agency report highlights importance of reducing antibiotic use
https://www.ema.europa.eu/en/news/multi-agency-report-highlights-importance-reducing-antibiotic-use
GD decision no. 2024-99 of 25/01/2024 – Changes to the organisational structure of the ANSM
https://ansm.sante.fr/actualites/decision-dg-ndeg-2024-99-du-25-01-2024-modification-de-lorganisation-de-lansm
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 January 2024
https://ansm.sante.fr/actualites/retour-dinformation-sur-le-prac-de-janvier-2024-8-11-janvier
Clinical trials on medicinal products: all transition applications must be submitted via the CTIS portal
https://ansm.sante.fr/actualites/essais-cliniques-de-medicaments-toutes-les-demandes-de-transition-doivent-etre-deposees-sur-le-portail-ctis